Morgan Stanley Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck & Co., Inc. (NYSE:MRK) had its target price boosted by equities researchers at Morgan Stanley from $112.00 to $113.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective points to a potential downside of 9.55% from the stock’s current price.

Other research analysts have also issued reports about the stock. Scotiabank upped their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $132.72.

Merck & Co., Inc. Price Performance

MRK stock traded down $1.07 during mid-day trading on Thursday, reaching $124.92. 3,146,903 shares of the company traded hands, compared to its average volume of 11,061,420. The company has a fifty day moving average price of $118.27 and a 200-day moving average price of $116.06. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $130.29. The company has a market capitalization of $308.54 billion, a P/E ratio of 35.19, a P/E/G ratio of 2.75 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 5.19 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Somerset Trust Co lifted its holdings in Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after acquiring an additional 81 shares during the period. Stonebridge Financial Group LLC lifted its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after acquiring an additional 81 shares in the last quarter. Pine Haven Investment Counsel Inc boosted its stake in Merck & Co., Inc. by 0.6% in the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock worth $1,834,000 after purchasing an additional 86 shares during the period. Chesapeake Wealth Management increased its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the last quarter. Finally, South Plains Financial Inc. increased its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after acquiring an additional 89 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck received fresh analyst support, including a Wells Fargo price-target increase to $150 and RBC’s reiterated outperform rating with a $142 target, suggesting meaningful upside from current levels. Analyst Target Update
• Positive Sentiment: Recent oncology milestones for KEYTRUDA, including U.S. and EU approvals in breast and bladder cancer, reinforce the importance of Merck’s biggest drug franchise and may help offset future patent-expiration concerns. KEYTRUDA Approvals Article
• Positive Sentiment: Merck also secured a new HIV access agreement for its once-daily treatment IDVYNSO, adding another incremental growth and commercialization datapoint for investors. HIV Access Deal Article
• Neutral Sentiment: Several recent market notes focus on Merck’s valuation and technical setup, with the stock trading above its 50-day and 200-day moving averages; that points to constructive momentum, but not a clear new catalyst by itself. Technical Analysis Article
• Neutral Sentiment: Zacks said MRK has been one of its most-watched stocks recently, which highlights elevated investor interest but does not, on its own, change the business outlook. Investor Attention Article
• Negative Sentiment: Recent commentary also reminds investors that Merck still faces longer-term headwinds from patent and vaccine pressure, which could limit upside if pipeline execution slows. Top Research Reports Article

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.